36,753 Shares in Boston Scientific Corporation $BSX Purchased by Purewater Capital LLC

Purewater Capital LLC acquired a new position in Boston Scientific Corporation (NYSE:BSX) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 36,753 shares of the medical equipment provider’s stock, valued at approximately $1,604,000. Boston Scientific comprises about 1.3% of Purewater Capital LLC’s holdings, making the stock its 17th largest holding.

Several other large investors have also recently modified their holdings of the company. Kelleher Financial Advisors acquired a new stake in Boston Scientific in the second quarter valued at approximately $25,000. Clal Insurance Enterprises Holdings Ltd acquired a new position in shares of Boston Scientific during the first quarter worth $28,000. Nvwm LLC increased its position in shares of Boston Scientific by 526.2% during the third quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 542 shares in the last quarter. Rakuten Securities Inc. acquired a new position in shares of Boston Scientific during the second quarter worth $30,000. Finally, Kings Path Partners LLC purchased a new stake in shares of Boston Scientific during the 3rd quarter valued at $31,000. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, Director David C. Habiger purchased 2,100 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director owned 17,160 shares in the company, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig purchased 5,000 shares of the company’s stock in a transaction on Friday, July 31st. The shares were purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the purchase, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought a total of 194,522 shares of company stock valued at $9,385,210 in the last ninety days. Company insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Stifel Nicolaus set a $60.00 price objective on Boston Scientific in a research report on Wednesday, July 29th. Rothschild & Co Redburn dropped their target price on Boston Scientific from $106.00 to $78.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Oppenheimer reduced their target price on Boston Scientific from $85.00 to $65.00 and set an “outperform” rating on the stock in a research report on Monday, September 21st. Raymond James Financial reiterated an “outperform” rating and issued a $57.00 price target (down from $78.00) on shares of Boston Scientific in a research note on Thursday, July 30th. Finally, UBS Group lowered their price target on Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $68.23.

Boston Scientific Trading Down 0.0%

Shares of Boston Scientific stock opened at $45.67 on Monday. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 12-month low of $41.38 and a 12-month high of $105.65. The firm has a market capitalization of $66.19 billion, a price-to-earnings ratio of 18.49, a PEG ratio of 1.10 and a beta of 0.58. The firm’s 50 day simple moving average is $45.46 and its two-hundred day simple moving average is $49.06.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter last year, the company posted $0.75 earnings per share. The business’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts predict that Boston Scientific Corporation will post 3.24 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.